Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection

Figures & data

Table 1 Anagraphic Clinical Features of Enrolled Patients

Age (Median, IQR)	59.2 (27–64)
Gender
M	40 (77%)
F	12 (23%)
HCV-RNA (IU/mL; median, IQR)	720.000 (21.000–1.670.000)
Genotype
1a	22 (42.3%)
1b	5 (9.6%)
2	3 (5.8%)
3	17 (32.7%)
4	5 (9.6%)
Staging (Metavir score)
F0	6 (11.5%)
F1	13 (25%)
F2	7 (13.5%)
F3	15 (28.8%)
F4	11 (21.2%)
Clinical cirrhosis (n, %)	11 (21.2%)
Child Pugh stage (n, %)
(among clinical cirrhosis)
A	11 (100%)
MELD (among clinical cirrhosis) (median, IQR)	9 (6–13)
Antiviral therapy
Sofosbuvir-Ledipasvir	10 (19.2%)
Sofosbuvir-Ribavirin	2 (3.8%)
Sofosbuvir-Daclatasvir	13 (25%)
Sofosbuvir-Velpatasvir	17 (32.7%)
Glecaprevir-Pibrentasvir	9 (17.3%)
Sofosbuvir-Simperevir	1 (2%)
CDC Classification System for HIV Infection	A: 15 (28.9%)
	B: 21 (40.4%)
	C: 16 (30.7%)
HIV-RNA (copies/mL, median, IQR)	532.380 (65.180–1.370.000)
Lymphocytes (cell/µL, median, IQR)	1190 (160–1980)
CD4+ pre-DAA (cell/µL, median, IQR)	724 (203–1656)
Albumin (g/dl; median, IQR)	3.5 (2.4–4.1)
Platelets (elements/µL; median, IQR)	157.000 (73.000–342.000)
INR (median, IQR)	1.1 (0.7–1.5)
ALT (IU/l, median, IQR)	69 (26–153)
AST (IU/l, median, IQR)	62 (23–132)
Tot. Bil. (mg/dl; median, IQR)	1.1 (0.7–1.7)

Abbreviations: INR, International Normalized Ratio; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase.

Table 2 CD4+ T Cell Count in Patients with HIV-HCV Coinfection by Pre-DAA, by SVR12 and by SVR48

Total HIV/HCV co- Infected (52)	Nadir CD4*	CD4 pre-DAAs*	CD4 SVR12*	CD4 SVR48*
A1 (0)
A2 (6)	363 (307–460)	774 (355–1656)	800 (558–1815)	780 (542–1720)
A3 (9)	126 (93–157)	426 (203–1027)	438 (201–721)	421 (117–725)
B1 (2)	544 (418–670)	1011 (971–1051)	1018 (951–1085)	1039.5 (989–1090)
B2 (7)	254 (201–300)	1139 (663–1397)	1123 (695–1729)	1008 (681–1120)
B3 (12)	110,5 (16–195)	620 (346–962)	626.5 (355–1103)	646.5 (402–925)
C1 (0)
C2 (1)	311	854	742	845
C3 (15)	106 (8–190)	475 (332–790)	468 (220–853)	504 (246–853)
	190 (16–670)	724 (203–1656)	684 (201–1815)	713 (117–1720)
HIV/HCV co-infected without cirrhosis (39)
A1 (0)
A2 (4)	363 (307–460)	896 (774–1656)	880 (800–1815)	901 (780–1720)
A3 (6)	194 (93–157)	675 (319–1027)	698 (387–622)
B1 (2)	544 (418–670)	1011 (971–1051)	1018 (951–1085)	1039.5 (989–1090)
B2 (6)	255,5 (191–300)	999,5 (663–1397)	980 (695–1729)	1012 (681–1120)
B3 (11)	101 (16–195)	688 (346–962)	679 (355–1103)	724 (402–925)
C1 (0)
C2 (1)	311	854	742	845
C3 (10)	62,5 (8–190)	506 (332–790)	480.5 (220–846)	497.5 (273–853)
	225 (8–670)	771 (319–1656)	720 (220–1815)	783 (273–1720)
HIV/HCV co-infected with Cirrhosis (12)
A1 (0)
A2 (2)	559 (355–408)	566 (355–422)	574 (558–590)	571.5 (542–601)
A3 (3)	125 (117–155)	390 (203–524)	438 (201–721)	421 (117–725)
B1 (0)
B2 (1)	254	1139	1148	848
B3 (1)	187	483	601	569
C1 (0)
C2 (0)
C3 (5)	140 (88–159)	436 (351–696)	353 (310–853)	504 (246–715)
	220 (88–408)	554.5 (203–696)	587.5 (201–853)	570.5 (117–725)

Notes: *Quantitative data are expressed as median and IQR in brackets. SVR12 weeks and SVR48 weeks.